Updated
Reviewed
Appendix A: Key to Acronyms
Study and Trial Names
Acronym/Abbreviation | Name |
---|---|
ACTG | AIDS Clinical Trials Group |
ADVANCE | Assessing Donor Variability And New Concepts in Eligibility |
ARDENT | ACTG A5257 trial |
ARTEMIS | Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
D:A:D | Data Collection on Adverse Events of Anti-HIV Drugs |
ECHO | Evidence for Contraceptive Options in HIV |
ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
FLAIR | First Long-Acting Injectable Regimen |
FLAMINGO | Dolutegravir Compared to Darunavir/Ritonavir, Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors |
HPTN | HIV Prevention Trials Network |
NADIA | Nucleosides And Darunavir/Dolutegravir In Africa |
NAMSAL | New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries |
STaR | Single-Tablet Regimen |
START | Strategic Timing of AntiRetroviral Treatment |
Appendix A: Key to Acronyms
Study and Trial Names
Acronym | Name |
---|---|
ACTG | AIDS Clinical Trials Group |
ADVANCE | Assessing Donor Variability And New Concepts in Eligibility |
ARDENT | ACTG A5257 trial |
ARTEMIS | Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
D:A:D | Data Collection on Adverse Events of Anti-HIV Drugs |
ECHO | Evidence for Contraceptive Options in HIV |
ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
FLAIR | First Long-Acting Injectable Regimen |
FLAMINGO | Dolutegravir Compared to Darunavir/Ritonavir, Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors |
HPTN | HIV Prevention Trials Network |
NADIA | Nucleosides And Darunavir/Dolutegravir In Africa |
NAMSAL | New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries |
STaR | Single-Tablet Regimen |
START | Strategic Timing of AntiRetroviral Treatment |
Download Guidelines
- Section Only PDF (122.37 KB)
- Full Guideline PDF (4.73 MB)
- Recommendations Only PDF (400.39 KB)
- Tables Only PDF (2.37 MB)